Fla. Stat. 499.007
Misbranded drug or device


(1)

If its labeling is in any way false or misleading.

(2)

If in package form, it does not bear a label containing:The name and place of business of the manufacturer, repackager, or distributor of the finished dosage form of the drug. For the purpose of this paragraph, the finished dosage form of a prescription drug is that form of the drug which is, or is intended to be, dispensed or administered to the patient and requires no further manufacturing or processing other than packaging, reconstitution, and labeling; andAn accurate statement of the quantity of the contents in terms of weight, measure, or numerical count. However, under this section, reasonable variations are permitted, and the department shall establish by rule exemptions for small packages.

(a)

The name and place of business of the manufacturer, repackager, or distributor of the finished dosage form of the drug. For the purpose of this paragraph, the finished dosage form of a prescription drug is that form of the drug which is, or is intended to be, dispensed or administered to the patient and requires no further manufacturing or processing other than packaging, reconstitution, and labeling; and

(b)

An accurate statement of the quantity of the contents in terms of weight, measure, or numerical count. However, under this section, reasonable variations are permitted, and the department shall establish by rule exemptions for small packages.

(3)

If it is an active pharmaceutical ingredient in bulk form and does not bear a label containing:The name and place of business of the manufacturer, repackager, or distributor; andAn accurate statement of the quantity of the contents in terms of weight, measure, or numerical count.

(a)

The name and place of business of the manufacturer, repackager, or distributor; and

(b)

An accurate statement of the quantity of the contents in terms of weight, measure, or numerical count.

(4)

If any word, statement, or other information required by or under this part to appear on the label or labeling is not prominently placed thereon with such conspicuousness as compared with other words, statements, designs, or devices in the labeling, and in such terms, as to render the word, statement, or other information likely to be read and understood under customary conditions of purchase and use.

(5)

If it is a drug and is not designated solely by a name recognized in an official compendium and its label does not bear:The common or usual name of the drug, if any; andIn case it is fabricated from two or more ingredients, the common or usual name and quantity of each active ingredient.

(a)

The common or usual name of the drug, if any; and

(b)

In case it is fabricated from two or more ingredients, the common or usual name and quantity of each active ingredient.

(6)

If its labeling does not bear:Adequate directions for use; andAdequate warnings against use in those pathological conditions in which its use may be dangerous to health or against use by children if its use may be dangerous to health, or against unsafe dosage or methods or duration of administration or application, in such manner and form as are necessary for the protection of users.

(a)

Adequate directions for use; and

(b)

Adequate warnings against use in those pathological conditions in which its use may be dangerous to health or against use by children if its use may be dangerous to health, or against unsafe dosage or methods or duration of administration or application, in such manner and form as are necessary for the protection of users.

(7)

If it purports to be a drug the name of which is recognized in the official compendium and it is not packaged and labeled as prescribed therein. However, the method of packaging may be modified with the consent of the department.

(8)

If it has been found by the department to be a drug liable to deterioration and it is not packaged in such form and manner, and its label bears a statement of such precautions, as the department by rule requires as necessary to protect the public health. Such rule may not be established for any drug recognized in an official compendium until the department has informed the appropriate body charged with the revision of such compendium of the need for such packaging or labeling requirements and that body has failed within a reasonable time to prescribe such requirements.

(9)

If it is:A drug and its container or finished dosage form is so made, formed, or filled as to be misleading;An imitation of another drug; orOffered for sale under the name of another drug.

(a)

A drug and its container or finished dosage form is so made, formed, or filled as to be misleading;

(b)

An imitation of another drug; or

(c)

Offered for sale under the name of another drug.

(10)

If it is dangerous to health when used in the dosage or with the frequency or duration prescribed, recommended, or suggested in the labeling of the drug.

(11)

If it is, purports to be, or is represented as a drug composed wholly or partly of insulin and it is not from a batch with respect to which a certificate has been issued pursuant to s. 506 of the federal act, which certificate is in effect with respect to the drug.

(12)

If it is, purports to be, or is represented as a drug composed wholly or partly of any kind of antibiotic requiring certification under the federal act and it is not from a batch with respect to which a certificate has been issued pursuant to s. 507 of the federal act, which certificate is in effect with respect to the drug. However, this subsection does not apply to any drug or class of drugs exempted by regulations adopted under s. 507(c) or (d) of the federal act.

(13)

If it is a drug intended for use by humans which is a habit-forming drug or which, because of its toxicity or other potentiality for harmful effect, or the method of its use, or the collateral measures necessary to its use, is not safe for use except under the supervision of a practitioner licensed by law to administer such drugs, or which is limited by an effective application under s. 505 of the federal act to use under the professional supervision of a practitioner licensed by law to prescribe such drug, if it is not dispensed only:Upon the written prescription of a practitioner licensed by law to prescribe such drug;Upon an oral prescription of such practitioner, which is reduced promptly to writing and filled by the pharmacist; orBy refilling any such written or oral prescription, if such refilling is authorized by the prescriber in the original prescription or by oral order which is reduced promptly to writing and filled by the pharmacist.

This subsection does not relieve any person from any requirement prescribed by law with respect to controlled substances as defined in the applicable federal and state laws.

(a)

Upon the written prescription of a practitioner licensed by law to prescribe such drug;

(b)

Upon an oral prescription of such practitioner, which is reduced promptly to writing and filled by the pharmacist; or

(c)

By refilling any such written or oral prescription, if such refilling is authorized by the prescriber in the original prescription or by oral order which is reduced promptly to writing and filled by the pharmacist.

(14)

If it is a drug that is subject to paragraph (13)(a), and if, at any time before it is dispensed, its label does not bear the statement:“Caution: Federal Law Prohibits Dispensing Without Prescription”;“Rx Only”;The prescription symbol followed by the word “Only”; or“Caution: State Law Prohibits Dispensing Without Prescription.”

(a)

“Caution: Federal Law Prohibits Dispensing Without Prescription”;

(b)

“Rx Only”;

(c)

The prescription symbol followed by the word “Only”; or

(d)

“Caution: State Law Prohibits Dispensing Without Prescription.”

(15)

If it is a drug that is not subject to paragraph (13)(a), if at any time before it is dispensed its label bears the statement of caution required in subsection (14).

(16)

If it is a color additive, the intended use of which in or on drugs is for the purpose of coloring only and its packaging and labeling are not in conformity with the packaging and labeling requirements that apply to such color additive and are prescribed under the federal act.

(17)

A drug dispensed by filling or refilling a written or oral prescription of a practitioner licensed by law to prescribe such drug is exempt from the requirements of this section, except subsections (1), (9), (11), and (12) and the packaging requirements of subsections (7) and (8), if the drug bears a label that contains the name and address of the dispenser or seller, the prescription number and the date the prescription was written or filled, the name of the prescriber and the name of the patient, and the directions for use and cautionary statements. This exemption does not apply to any drug dispensed in the course of the conduct of a business of dispensing drugs pursuant to diagnosis by mail or to any drug dispensed in violation of subsection (13). The department may, by rule, exempt drugs subject to s. 499.062 from subsection (13) if compliance with that subsection is not necessary to protect the public health, safety, and welfare.

Source: Section 499.007 — Misbranded drug or device, https://www.­flsenate.­gov/Laws/Statutes/2024/0499.­007 (accessed Aug. 7, 2025).

499.01
Permits
499.001
Florida Drug and Cosmetic Act
499.002
Purpose, administration, and enforcement of and exemption from this part
499.03
Possession of certain drugs without prescriptions unlawful
499.003
Definitions of terms used in this part
499.04
Fee authority
499.05
Rules
499.005
Prohibited acts
499.06
Embargoing, detaining, or destroying article or processing equipment which is in violation of law or rule
499.006
Adulterated drug or device
499.007
Misbranded drug or device
499.008
Adulterated cosmetics
499.009
Misbranded cosmetics
499.012
Permit application requirements
499.015
Registration of drugs and devices
499.023
New drugs
499.024
Drug product classification
499.025
Drug products in finished, solid, oral dosage form
499.026
Notification of manufacturer prescription drug price increases
499.028
Drug samples or complimentary drugs
499.029
Cancer Drug Donation Program
499.032
Phenylalanine
499.033
Ephedrine
499.035
Dimethyl sulfoxide (DMSO)
499.036
Restrictions on sale of dextromethorphan
499.039
Sale, distribution, or transfer of harmful chemical substances
499.041
Schedule of fees for drug, device, and cosmetic applications and permits, product registrations, and free-sale certificates
499.051
Inspections and investigations
499.0051
Criminal acts
499.052
Records of interstate shipment
499.0054
Advertising and labeling of drugs, devices, and cosmetics
499.055
Reports and dissemination of information by department
499.057
Expenses and salaries
499.062
Seizure and condemnation of drugs, devices, or cosmetics
499.065
Inspections
499.066
Penalties
499.067
Denial, suspension, or revocation of permit, certification, or registration
499.0121
Storage and handling of prescription drugs
499.0285
International Prescription Drug Importation Program
499.0295
Experimental treatments for terminal conditions
499.0661
Cease and desist orders
499.01201
Agency for Health Care Administration review and use of statute and rule violation or compliance data
499.01211
Drug Wholesale Distributor Advisory Council
499.02851
Federal arrangement to operate a pilot program for importing prescription drugs

Current through Fall 2025

§ 499.007. Misbranded drug or device's source at flsenate​.gov